A Bohemia-based firm is introducing its wearable specialty lighting for brain surgeons. The system aims help enable doctors to quickly operate during brain tumor surgery.
Designs for Vision recently introduced its Real FGS System, a tool for a procedure known as fluorescence guided surgery, which enables surgeons to more quickly spot and remove tumors. The technology comprises “advance wearable specialty lighting and appropriate optical filters” that provide optimized lighting conditions during brain tumor surgery, according to the company.
This system, the company claims, would make surgery to specifically remove giloma, a rare tumor that develops in the brain and spinal cord, more accessible. The tool improves the ability to see the tumor tissue, aiding in the removal of the material.
The wearable technology “makes fluorescence guided surgery more accessible by lowering the entry cost to a fraction of the previous technology,” Ken Bragança, vice president of operations at Designs for Vision, said in a statement. “Rather than just the largest, best-funded hospitals being able to provide this technology, the Reveal FGS System brings the miracle of fluorescence guided surgery to all hospitals.
According to the company, most surgeons operating on gilomas use high-cost lighting microscopes, and in part because of those high costs, there are fewer surgeries performed. The company claims that its $8,000 system, more medical centers would have access to the tool, making the complex surgery possible.
The wearable Reveal System provides easy to use blue light in the 405 nm wavelength combined with wearable lenses with unique high band pass filters allowing the user to see the pattern of tumor presence that differentiate from not malignant tissue. This technology allows improved visualization of tumors previously not visible under standard lighting conditions. Additionally, neurosurgeons who have tested it report greater flexibility of movement, as they can view tumor tissue from greater ranges of angles and positions than they would via a fixed microscope.
The company began working on the FGS System back in December 2019, after some of its representatives attended a symposium whose keynote was delivered by Dr. Walter Stummer, now director of the Department of Neurosurgery of the University Hospital Münster and Past President of the German Society for Neurosurgery. Stummer, along with Dr. Herbert Stepp from the University of Munich, worked with the Designs for Vision team in developing the system.
A three-month testing phase of the Reveal FGS System ran from March through May of 2021. Designs for Vision approached several leading oncologic specialists within neurological surgery in the United States who agreed to participate in the beta testing phase.
The system “allows you to get a greater percentage of the fluorescent light to be visualized, and I think increases the sensitivity and specificity of the technique over the microscope,” Dr. Theodore Schwartz, a professor of minimally invasive neurosurgery at Weill Cornell Medicine, New York Presbyterian Hospital, said in a statement about the testing phase.
“I now use the Reveal FGS System as another tool in my approach to remove suspected high-grade gliomas because ease of use and a better overview of the entire operative field,” he added.